Figure 2. Time to Psoriasis Relapse.

Time to psoriasis relapse curves for the switched to abatacept group (abatacept group) and the continued with ustekinumab group (ustekinumab group) are displayed as the estimated survival function for interval-censored data. For participants who experienced a psoriasis relapse, the censoring interval was derived from the time points of the participants’ last 2 Psoriasis Area and Severity Index (PASI) evaluations, which were typically 4 weeks apart. For participants who did not experience a psoriasis relapse, the time to relapse was right-censored at the time point of the last PASI evaluation. For participants randomized to the abatacept group, the last dose of ustekinumab was administered at week 4. For participants randomized to the ustekinumab group, the last dose of ustekinumab was administered at week 28. ITT indicates intention to treat.